Table 4 Univariate and Multivariate Analyses Evaluating Overall Survival.
Variable | Univariate Analysis* | Multivariate analysis** | |||||
|---|---|---|---|---|---|---|---|
Model 1 using PET staging | Model 2 using pathologic T staging | ||||||
5-year OS | χ2 | p-value | HR (95% CI) | p-value | HR (95% CI) | p- value | |
Sex | 3.482 | 0.062 | 0.053 | 0.080 | |||
Male | 74.2% | Reference | Reference | ||||
Female | 88.7% | 0.322 (0.10–1.02) | 0.36 (0.11–1.13) | ||||
Age | 0.524 | 0.469 | Not included | Not included | |||
<60 | 79.0% | ||||||
≥60 | 73.5% | ||||||
R0 resection | 0.017 | 0.896 | Not included | Not included | |||
Yes | 75.1% | ||||||
No | 75.0% | ||||||
Adjuvant Tx | 2.511 | 0.113 | Not included | Not included | |||
No | 76.0% | ||||||
Yes | 71.3% | ||||||
Locations | 4.337 | 0.631 | Not included | Not included | |||
Tumor length*** | 0.373 | 0.542 | Not included | Not included | |||
<2.5 cm | 75.9% | ||||||
≥2.5 cm | 74.1% | ||||||
Tumor differentiation | 2.161 | 0.339 | Not included | Not included | |||
G1 | 82.4% | ||||||
G2 | 73.6% | ||||||
G3 | 71.7% | ||||||
Nodal metastasis | 5.435 | 0.020 | 0.177 | 0.144 | |||
No | 77.0% | Reference | Reference | ||||
Yes | 70.9% | 1.33 (0.88–1.99) | 0.73 (0.48–1.11) | ||||
Pathologic T stage | 11.488 | 0.003 | Not included | 0.022 | |||
Tis + T1a | 77.8% | Reference | |||||
T1b | 77.6% | 1.25 (0.75–2.09) | |||||
T2 | 62.0% | 2.18 (1.20–3.94) | |||||
Clinical T stage (EUS) | 1.198 | 0.753 | Not included | Not included | |||
Less than T1a | 75.9% | ||||||
T1b | 77.1% | ||||||
T2 | 72.5% | ||||||
T3 | 70.0% | ||||||
PET staging group | 17.367 | <0.001 | <0.001 | Not included | |||
A: SUVmax ≤ 3.05 | 80.6% | Reference | |||||
B: SUVmax 3.06–5.64 | 78.7% | 1.38 (0.85–2.25) | |||||
C: SUVmax ≥ 5.65 | 59.5% | 2.66 (1.66–4.25) | |||||
